Best Peptides for Longevity: Evidence-Based Rankings

Why Peptides Are Uniquely Positioned for Longevity

Conventional supplements—vitamins, minerals, and plant extracts—work primarily through antioxidant and anti-inflammatory pathways. While valuable, these mechanisms address only surface-level aspects of aging. Peptides, by contrast, are short chains of amino acids that can directly influence the fundamental biological processes underlying aging: hormone signaling, immune function, muscle preservation, bone density, cognitive health, and cellular repair mechanisms.

Unlike broad-spectrum supplements, peptides function as signaling molecules that communicate directly with cellular receptors. They can activate growth hormone secretion, modulate immune cell differentiation, suppress myostatin (the "brake" on muscle growth), restore thymic function, improve vascular health, and enhance neuroplasticity. This specificity makes them far more targeted than conventional interventions.

The evidence base for peptides in longevity research has expanded significantly, with multiple randomized controlled trials and meta-analyses now demonstrating concrete benefits for fracture prevention, immune restoration, body composition, cardiovascular protection, and cognitive function—all critical determinants of healthspan and lifespan. This article ranks the peptides with the strongest evidence for longevity outcomes.

Ranking Methodology

Peptides are ranked by evidence tier for longevity specifically. Tier 4 represents strong evidence from multiple RCTs and meta-analyses with direct longevity-relevant outcomes. Tier 3 represents probable efficacy supported by human RCTs and mechanistic evidence, but lacking large-scale replication or direct lifespan data. Only peptides meeting these thresholds are included.

1. Abaloparatide — Tier 4 Evidence

What It Is: Abaloparatide (brand name Tymlos) is a synthetic analog of parathyroid hormone-related peptide (PTHrP). It stimulates osteoblasts (bone-building cells) preferentially over osteoclasts (bone-resorbing cells), making it one of the few agents that actually increases bone formation rather than merely slowing bone loss.

Evidence for Longevity: Abaloparatide is the only peptide on this list with Tier 4 evidence—the highest tier. It reduces fracture risk, which is directly relevant to longevity in aging populations. Osteoporotic fractures, particularly hip fractures, are major drivers of morbidity, mortality, loss of independence, and reduced lifespan in older adults.

In the landmark ACTIVE trial (1,645 postmenopausal women, 18 months), abaloparatide reduced major osteoporotic fractures by 69% (95% CI 38-85%) compared to placebo and reduced any clinical fracture by 43% (95% CI 9-64%). A network meta-analysis of 17 studies confirmed abaloparatide's superiority to teriparatide for non-vertebral fractures (OR 0.87, 95% CI 0.80-0.95) and hip fractures (OR 0.81, 95% CI 0.71-0.93)—the fracture types most strongly associated with mortality.

Dosing: 80 mcg once daily via subcutaneous injection

Cost: $1,800–$2,800 per month

Best For: Postmenopausal women and older men with osteoporosis or osteopenia; anyone with a family history of hip fracture; individuals at high fracture risk. This is the peptide with the most direct longevity evidence.

2. Thymalin — Tier 3 Evidence

What It Is: Thymalin is a thymic peptide extract that mimics the endocrine function of the thymus gland, which involutes (shrinks) significantly with age. It contains bioactive peptides that promote T cell maturation and immune restoration in aging populations.

Evidence for Longevity: Thymalin shows the strongest longevity signal among Tier 3 peptides. In a human RCT spanning 6-8 years across 266 elderly subjects, thymalin monotherapy reduced all-cause mortality by 2.0-2.1-fold during and after treatment. Combined with epithalamin (another thymic peptide), the mortality reduction reached 4.1-fold, with concurrent reductions in acute respiratory disease incidence (2.0-2.4-fold), ischemic heart disease, hypertension, osteoarthritis, and osteoporosis.

These outcomes suggest thymalin works through thymic restoration and immune system rejuvenation—a core mechanism of aging prevention.

Dosing: 5–20 mg once daily via subcutaneous injection

Cost: $40–$120 per month

Best For: Older adults (age 60+) seeking broad immune support and longevity benefits; individuals with recurrent infections or poor vaccine response; those concerned with age-related disease prevention.

3. Cerebrolysin — Tier 3 Evidence

What It Is: Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue. It contains peptide fractions that cross the blood-brain barrier and promote neuroplasticity, reduce neuroinflammation, and enhance cognitive function.

Evidence for Longevity: Cerebrolysin demonstrates probable efficacy for cognitive longevity and neuroprotection. A meta-analysis of 6 human RCTs found cerebrolysin improved cognitive function in mild-to-moderate Alzheimer's disease with a standardized mean difference of -0.40 (p=0.0031) at 4 weeks, and achieved a 76% responder rate versus 57% for placebo (p=0.007). Mouse studies in a CADASIL model (vascular dementia) showed cerebrolysin prolonged lifespan, reduced epigenetic aging, improved spatial memory, and increased expression of longevity-associated proteins SIRT6 and CGRP.

Cognitive decline and neurodegeneration are major contributors to morbidity in aging; preservation of cognitive function is a key pillar of longevity.

Dosing: 5–30 mL (215–1,290 mg peptide fraction) once daily for acute courses; 3–5 times per week for off-label cognitive support. Administered via intramuscular or intravenous injection.

Cost: $80–$400 per month

Best For: Individuals with age-related cognitive decline, mild cognitive impairment, or early Alzheimer's disease; those with vascular dementia or stroke history; anyone prioritizing cognitive longevity.

4. Thymopentin (TP-5) — Tier 3 Evidence

What It Is: Thymopentin is a five-amino-acid peptide derived from thymosin that enhances T cell differentiation and maturation. It is structurally simpler than thymalin but targets similar immune restoration pathways.

Evidence for Longevity: Thymopentin shows consistent immune and cardiac benefits in aging populations. In chronic heart failure patients (n=96, age >60), thymopentin increased left ventricular ejection fraction (LVEF), elevated CD4+ T cell and NK cell counts, decreased brain natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hsCRP) significantly (p<0.01), and improved 6-minute walking distance versus standard care alone. In aging male cardiac patients (n=156, mean age 57+), thymopentin reduced NT-proBNP, CRP, and the Th1/Th2 inflammatory ratio while improving LVEF and exercise capacity after 3 months.

Cardiac function and immune resilience are critical to longevity; these dual benefits make thymopentin valuable for aging cardiovascular health.

Dosing: 1 mg, 3 times per week via subcutaneous injection

Cost: $40–$120 per month

Best For: Older adults with cardiac risk factors or heart failure; those with recurrent infections or immune dysfunction; individuals seeking combined immune and cardiovascular longevity support.

5. Thymosin Alpha-1 — Tier 3 Evidence

What It Is: Thymosin Alpha-1 is a 28-amino-acid peptide hormone produced by the thymus gland that activates dendritic cells and enhances Th1 immune responses. It is commercially available as Thymalfasin.

Evidence for Longevity: Thymosin Alpha-1 demonstrates probable efficacy for immune restoration in aging. In elderly men (ages 65–99, n=85, double-blind RCT), those receiving thymosin alpha-1 plus standard influenza vaccine showed significantly higher antibody response rates compared to placebo with vaccine alone—a key marker of immune competence. More recently, in depressed CVID (common variable immunodeficiency) patients, all 5 subjects receiving thymosin alpha-1 showed 52% average reduction in depression scores (versus 36% in standard care) and elevated naïve/memory CD4+ and CD8+ T cell ratios.

Immune senescence is a hallmark of aging; restoration of vaccine responsiveness and Th1 function supports longevity through infectious disease prevention.

Dosing: 1.6 mg twice weekly via subcutaneous injection

Cost: $60–$200 per month

Best For: Older adults with poor vaccine response; immunocompromised individuals; those with recurrent infections; people seeking accessible, affordable immune restoration.

6. Follistatin 344 — Tier 3 Evidence

What It Is: Follistatin 344 is a myokine peptide that inhibits myostatin and activin—negative regulators of muscle growth. By suppressing these "brakes," follistatin 344 permits muscle hypertrophy and improved muscle quality, particularly when combined with resistance exercise.

Evidence for Longevity: Follistatin 344 addresses sarcopenia, the age-related loss of skeletal muscle mass and strength that drives frailty and reduced lifespan. In healthy older women (n=96, RCT), resistance exercise plus essential amino acid supplementation elevated the follistatin/myostatin ratio significantly, correlating with muscle mass gains. In elderly men (n=60, RCT), soy milk plus resistance training increased follistatin by 7.8%, decreased myostatin by 0.5%, and decreased GDF11 (another myostatin family member) by 9.0%.

While these are modest single-intervention effects, the consistent elevation of the follistatin/myostatin ratio across studies supports its role in combating sarcopenia—a direct longevity threat.

Dosing: 100 mcg once daily for 10 days, then off (cyclic protocol) via subcutaneous injection

Cost: $60–$200 per month

Best For: Older adults with sarcopenia or frailty; individuals unable to build muscle despite resistance training; anyone combining strength training with peptide support for maximal muscle preservation.

7. Tesamorelin — Tier 3 Evidence

What It Is: Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates pituitary GH secretion. It is FDA-approved for abdominal lipodystrophy in HIV+ patients.

Evidence for Longevity: Tesamorelin improves body composition and metabolic markers relevant to longevity. In HIV+ adults with abdominal obesity (n=73, 6-month RCT), tesamorelin reduced waist circumference significantly more than standard care (p<0.05). Across pooled analyses (n=341), tesamorelin increased IGF-1 levels and trunk muscle density (1.56–4.86 Hounsfield units across four muscle groups, all p<0.005) compared to placebo.

These changes—reduced visceral adiposity, increased muscle density, and restored IGF-1—are associated with improved metabolic health and reduced all-cause mortality risk, supporting its longevity potential.

Dosing: 2 mg once daily via subcutaneous injection

Cost: $80–$400 per month

Best For: Older adults with central obesity and metabolic dysfunction; HIV+ individuals; those seeking GH axis restoration without exogenous GH use.

8. GHRP-2 (Growth Hormone Releasing Peptide-2) — Tier 3 Evidence

What It Is: GHRP-2 is a synthetic hexapeptide that acts on ghrelin receptors to stimulate GH secretion from the pituitary. It maintains pulsatile GH secretion patterns more physiologically than exogenous GH.

Evidence for Longevity: GHRP-2 robustly stimulates GH and IGF-1 secretion in humans. In postmenopausal women (n=10, RCT), GHRP-2 infusion amplified GH burst mass 1.9- to 8.8-fold when combined with estradiol. In healthy elderly (n=17, observational study), 30-day continuous subcutaneous infusion maintained pulsatile GH secretion elevated >1.8-fold on days 14 and 30, sustaining elevated IGF-I, IGFBP-3, and IGFBP-5 at a plateau.

The GH/IGF-1 axis is central to muscle mass, bone density, immune function, and metabolic health—all longevity pillars. However, GHRP-2 lacks direct human lifespan data, preventing a higher evidence tier.

Dosing: 100–300 mcg, 2–3 times daily via subcutaneous injection

Cost: $30–$90 per month

Best For: Older adults with age-related GH decline; those seeking GH axis restoration without exogenous GH; individuals focused on muscle and bone preservation.

9. Ibutamoren (MK-677) — Tier 3 Evidence

What It Is: Ibutamoren is an oral ghrelin mimetic that stimulates GH and IGF-1 secretion through the ghrelin receptor. Unlike GHRP-2, it is orally bioavailable.

Evidence for Longevity: Ibutamoren restores GH axis function in elderly. At 25 mg/day, it increased mean 24-hour GH concentration by 97±23% in elderly subjects over 14 days (n=32, RCT), and elevated serum IGF-I from 141±21 to 265±29 µg/L (baseline to 4 weeks).

These GH/IGF-1 elevations support muscle preservation, bone density, and metabolic health. However, evidence is limited to 3 small, short-duration RCTs with no lifespan data, limiting it to Tier 3.

Dosing: 10–25 mg once daily, orally

Cost: $30–$80 per month

Best For: Older adults preferring oral over injectable peptides; those with age-related GH decline; individuals seeking accessible GH axis support.

10. GLP-1 (Glucagon-Like Peptide-1 Receptor Agonists) — Tier 3 Evidence

What It Is: GLP-1 receptor agonists (semaglutide, dulaglutide, tirzepatide) are incretin mimetics that improve glucose metabolism, promote satiety, and reduce inflammation. Multiple mechanisms suggest anti-aging potential.

Evidence for Longevity: GLP-1 agonists show suggestive epidemiological evidence for neuroprotection and vascular health. Observational analysis in long-term users revealed reduced incidence of dementia, Parkinson disease, and multiple sclerosis. In a propensity-matched cohort of 9,669 GLP-1 agonist users, these agents reduced hazard of non-exudative age-related macular degeneration compared to metformin (HR 0.68, 95% CI 0.56–0.84), insulin (HR 0.72, 95% CI 0.58–0.89), and statins (HR 0.70, 95% CI 0.57–0.87).

However, concerns exist regarding muscle mass loss and facial aging ("GLP-1 face"), complicating the longevity profile. Evidence remains mechanistic and observational rather than from dedicated longevity trials.

Dosing: 100–300 mcg once or twice daily via subcutaneous injection (formulation-dependent)

Cost: $40–$120 per month (varies by agent and source)

Best For: Type 2 diabetics or obese individuals seeking metabolic longevity; those with family history of neurodegenerative disease; individuals willing to monitor muscle mass during use.

11. Dulaglutide — Tier 3 Evidence

What It Is: Dulaglutide is a long-acting GLP-1 receptor agonist (brand name Trulicity) administered weekly. It improves glucose control and cardiovascular outcomes in type 2